Danyelza

Go or no go? Big decisions loom for Bristol and Sanofi
EP Vantage
Fri, 10/30/20 - 10:12 am
FDA
Bristol-Myers Squibb
aducanumab
Sanofi
sutimlimab
Y-mAbs
Danyelza